Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Immunome, Inc. < Previous 1 2 Next > Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity May 23, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports First Quarter 2023 Financial Results May 05, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports Fourth Quarter and Full Year 2022 Financial Results March 16, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at 13th Annual World ADC London Conference March 09, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board February 08, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets January 06, 2023 From Immunome, Inc. Via Business Wire Tickers ABBV IMNM Immunome Reports Third Quarter 2022 Financial Results November 14, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting November 09, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer August 23, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports Second Quarter 2022 Financial Results August 05, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1 July 06, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 June 09, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at the Jefferies Healthcare Conference June 02, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 May 23, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant May 19, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports First Quarter 2022 Financial Results May 12, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports Fourth Quarter and Full Year 2021 Financial Results March 28, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing February 08, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 January 10, 2022 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald December 07, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant December 01, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 November 29, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports Third Quarter 2021 Financial Results November 15, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at the Stifel Healthcare Conference November 09, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis October 20, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 07, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics September 30, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at the Cantor Global Healthcare Conference September 22, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit September 15, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing September 07, 2021 From Immunome, Inc. Via Business Wire Tickers IMNM < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.